Clinical Trial Update: IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating IRX-2 regimen in newly diagnosed stage II-IV A squamous cell carcinoma of the oral cavity has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Oral Cavity

Drugs mentioned

• IRX-2

Snippet

Sponsor: Brooklyn ImmunoTherapeutics, LLC | Conditions: Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Status: COMPLETED | Results posted: 2024-01-30